Thierry Bernard
On August 3, 2026, Mr. Thierry Bernard resigned from the Board of Directors of Neogen Corporation.
Highest-materiality recent filing
Neogen reports Q4 FY2026 revenue $225.3M, net loss $11.3M; core growth 4.3%
Q4 revenue $225.3M (flat YoY); core growth 4.3%; full-year revenue $870.4M, core growth 1.9%.
Neogen Q3 FY26 revenue $211.2M; net loss $17M; divests Genomics unit
Revenue $211.2M; Food Safety core growth +4.0%, Animal Safety core growth –8.7% on supplier challenges.
Neogen Q2 revenue $224.7M (-2.8% YoY); core growth +2.9%; raises FY guidance
Net loss of $15.9M; adjusted net income of $22.6M; adjusted EBITDA of $48.7M.
Neogen appoints Bryan Riggsbee as CFO effective Nov 3, 2025
Riggsbee named SVP & CFO, succeeding David Naemura who remains through end of 2025 to aid transition.
Neogen Q1 FY2026 revenue $209.2M, net income $36.3M; new CEO Mike Nassif
Revenue $209.2M, net income $36.3M; adjusted net income $9.4M, adjusted EBITDA $35.5M.
Neogen CFO & COO David Naemura resigns voluntarily; successor search underway
Naemura will remain CFO/COO until October filing of 10-Q, no later than Dec 31, 2025.
Neogen announces board retirement of William Boehm, appointment of Avi Pelossof effective Oct 23/24
William T. Boehm to retire from Neogen's Board effective Oct 23, 2025; served since 2011, chairs Audit Committee, member of Compensation & Talent Management Committee.
Neogen Q4 FY2025 revenue $225.5M; net loss $612.2M on goodwill impairment; adj. EPS $0.05
Revenue $225.5M; net loss $612.2M ($2.82 diluted loss) primarily from non-cash goodwill impairment.
Neogen appoints Mikhael Nassif as President and CEO effective August 11, 2025
Mikhael Nassif, former Siemens Healthineers Global President of Point-of-Care Diagnostics, appointed CEO.
Neogen Q3 FY2025: revenue $221M, net loss $11M; updates guidance
Net loss of $11.0M ($0.05 diluted EPS); adjusted net income of $20.9M ($0.10 adjusted EPS).
Neogen CEO John Adent to step down; board forms search committee
John Adent will remain CEO/President until successor appointed; then serve as Special Advisor through Oct 31, 2025.
Neogen Q2 net loss $456.3M ($2.10/share) on goodwill impairment; adj EPS $0.11
Revenue $231.3M; net loss $456.3M ($2.10 diluted) primarily from non-cash goodwill impairment.
Neogen Q1 net loss $12.6M; revenue down 5.3% YoY; guidance unchanged
Revenue $217.0M, down 5.3% YoY; core revenue declined 1.4%; currency headwind 3.9%.
Neogen Q4 revenue $236.8M down 2.1% YoY; net loss $0.02 EPS; guides FY25 rev $925-955M
Revenue $236.8M, down 2.1% YoY; core revenue grew 2.0% as FX headwind of 4.2% offset.
Neogen reports Q3 revenue up 4.8% to $228.8M but net loss of $2.0M; cuts FY2024 outlook
Net loss of $2.0M ($0.01 diluted EPS) vs net income $8.2M ($0.04) a year ago.
Neogen Q2 FY2024 revenue $229.6M, net loss $(0.02)/sh; lowers full-year outlook
Revenue $229.6M, roughly flat YoY; Food Safety +1.9%, Animal Safety -5.0%.
Neogen enters new severance agreements, amends bylaws, and holds annual meeting
New severance letters for CEO Adent, CFO Naemura, and other NEOs; 2x salary for CEO, 1x for others on non-Cause/Good Reason termination.
Neogen Q1 FY2024 revenue $229M (+73%); core revenue declines 1.3%; adj. EPS $0.11
Revenue $229.0M, +73% YoY driven by 3M Food Safety acquisition; core revenue ex-acquisition declined 1.3%.
Neogen Q4 revenue up 72.6% to $241.8M; net income $5.6M; FY2024 guidance issued
Q4 revenue $241.8M (+72.6% YoY); net income $5.6M ($0.03 EPS); adjusted net income $30.2M ($0.14 EPS).
Neogen Q3 revenue $218.3M (+70% YoY); adjusted EPS $0.12 vs $0.15 prior year
Revenue $218.3M (+70% YoY); core growth 4%, acquisition 68.1%, FX -1.9%.
Neogen Q2 revenue up 76% to $230M; GAAP net loss $41.8M; adjusted net income $31.4M
Revenue $230.0M, up 76.2% YoY; core revenue growth (ex-acquisitions & FX) 6.6%.
Neogen Q1 revenue up 3% to $132.3M; net income down to $0.05/sh due to $13.7M deal costs
Revenue $132.3M, up 3% (6% constant currency); organic growth 4%.
Neogen CFO Steve Quinlan to retire May 2023; David Naemura to succeed as CFO
CFO Steve Quinlan to retire effective May 31, 2023; has served since 2011.
On August 3, 2026, Mr. Thierry Bernard resigned from the Board of Directors of Neogen Corporation.
Replacing Mr. Tobin, Neogen appoints Andrea Wainer to Neogen’s Board of Directors, effective June 1, 2025.
announces that James P. Tobin has chosen to retire from the Company’s Board of Directors, effective May 31, 2025.
On April 9, 2025 Neogen Corporation (the “Company”) announced that John Adent, the Company’s CEO and President, will be stepping down.
Doug Jones, who will be retiring as Chief Operating Officer effective February 28, 2025
David Naemura has been appointed Chief Operating Officer effective January 1, 2025, in addition to his role as Chief Financial Officer.
Douglas E. Jones, Neogen’s Chief Operating Officer, has communicated his intent to retire in early 2025.
Neogen Corporation announced today that it has appointed Thierry Bernard to its Board of Directors.
David Naemura will continue as the Company’s Chief Financial Officer and Mr. Moylan will serve as the Company’s Principle Accounting Officer, replacing Mr. Naemura in that role.
John Moylan is appointed as Vice President, Corporate Controller, and Chief Accounting Officer of Neogen Corporation (the “Company”) effective April 15, 2024.
Darci Vetter has informed the Company that she will resign from her position as a member of the Neogen Corporation Board of Directors (the “Board”) and from all committees of the Board effective the day after the 2023 Annual Meeting of Neogen Shareholders.
David Naemura will be appointed as CFO of the Company, effective as of January 2, 2023
Max materiality 0.80 · Median 0.55 · Most common event leadership